Servier Egypt launches Tibsovo as first targeted therapy for IDH1-mutated cancers
Servier Egypt has launched Tibsovo (ivosidenib), the first targeted therapy available in…
Servier Egypt celebrates jubilee with new production line, cancer programme
Servier Egypt, part of the global Servier Group, has commemorated its 70th…